Acute and sub-chronic oral toxicity evaluation and gut microbiota modulation of indigenous Lactobacillus helveticus strains from Indonesia in rats Authors: Hery Kristiana, Medicia Kartawijaya, Lita Tuentifiany, Apriliana Wahyu Hartanti, Raymond R. Tjandrawinata Published: 2026 ABSTRACT Probiotics are widely used to support gastrointestinal health, but their safety must be evaluated on a strain-specific basis. Lactobacillus helveticus DLBSA201 and DLBSA202 are indigenous strains with previously demonstrated probiotic potential in vitro. However, their in vivo safety profile has not been fully assessed. This study aimed to evaluate the acute and sub-chronic oral toxicity of these strains and their effects on selected gut microbial parameters in Wistar rats. In the acute toxicity study, rats received a single oral dose of L. helveticus DLBSA201 or DLBSA202 at 2.5 × 1010, 2.5 × 1011, or 5 × 1011 CFU/rat. In the sub-chronic study, rats were orally administered a 1:1 mixture of both strains daily for 90 days at doses of 1 × 109, 1 × 1010, or 1 × 1011 CFU/rat/day. Clinical observations, hematological and biochemical parameters, histopathology, bacterial translocation, bacterial enzyme activity, and fecal microbiological analyses were evaluated. No mortality or treatment-related adverse effects were observed, and the LD50 of both strains was estimated to be greater than 5 × 1011 CFU/rat. No significant treatment-related toxicological abnormalities were detected in the sub-chronic study, with a NOAEL of 1 × 1011 CFU/rat/day. Probiotic administration was also associated with reduced harmful bacterial enzyme activity and altered selected fecal bacterial populations. In conclusion, L. helveticus DLBSA201 and DLBSA202 were well tolerated in Wistar rats at the tested dose range and study duration, and warrant further investigation using comprehensive microbiome and clinical approaches. Introduction The intricate relationship between the gut microbiota and human health has become increasingly evident in recent years. Dysbiosis, an imbalance in the gut microbiota, has been implicated in a wide range of health conditions, including inflammatory bowel disease, irritable bowel syndrome, and obesity [1], [2]. Consequently, modulation of gut microbiota through probiotic supplementation has attracted considerable attention as a potential strategy to maintain gastrointestinal and overall health. Recent studies have further highlighted the role of probiotics in immune regulation, intestinal barrier maintenance, and microbiota modulation [3], [4], [5]. Probiotics are defined as live microorganisms that confer health benefits when administered in adequate amounts (FAO/WHO, 2002). Numerous probiotic strains belonging to the genus Lactobacillus have been reported to exhibit beneficial properties, including antimicrobial activity, pathogen exclusion, enhancement of intestinal barrier function, antioxidant activity, and immunomodulatory effects [6], [7]. In particular, Lactobacillus helveticus has attracted considerable interest due to its potential therapeutic and functional applications in food and health industries. Previous studies have demonstrated that L. helveticus strains may produce bioactive peptides, inhibit pathogenic bacteria, modulate immune responses, and improve intestinal microbial balance [8], [9]. However, the beneficial effects and safety profiles of probiotics are considered strain-specific, highlighting the importance of independent evaluation for each candidate strain prior to human application [10], [11]. Indonesia, a country with rich biodiversity, offers a vast reservoir of indigenous microorganisms with potential probiotic properties. Among the indigenous isolates previously identified, Lactobacillus helveticus DLBSA201 and DLBSA202 demonstrated promising in vitro probiotic characteristics, including acid and bile salt tolerance, antimicrobial activity, and immunomodulatory potential [12]. In addition, the combination of these strains showed improved probiotic-associated activity in vitro compared with individual strains, suggesting potential synergistic effects [12]. Despite these promising findings, information regarding the in vivo safety profile and biological effects of these indigenous strains remains limited. Although many Lactobacillus species are classified as “Generally Recognized as Safe” (GRAS), safety evaluation remains essential because probiotic effects and potential risks are strain dependent [13], [14], [15]. Several studies have highlighted the importance of assessing probiotic safety through comprehensive toxicological evaluation, including acute and sub-chronic toxicity studies, bacterial translocation assessment, hematological and biochemical analysis, and histopathological examination [16], [17]. Furthermore, probiotic administration may influence intestinal bacterial enzyme activity, including β-glucuronidase and β-glucosidase, which are associated with harmful bacterial metabolism and intestinal health status [14]. However, limited studies have comprehensively evaluated both the toxicological profile and microbiological effects of indigenous L. helveticus strains in vivo. To evaluate the safety and efficacy of these indigenous strains in vivo, we conducted a comprehensive study involving animal models. This study assessed the acute and 90 days sub-chronic oral toxicity of L. helveticus DLBSA201 and DLBSA202 in Wistar rats. In addition to standard toxicological assessments, this study also investigated bacterial translocation, selected fecal microbial populations, and bacterial enzyme activity following probiotic administration. This work provides important baseline pre-clinical safety data and broader insight into the biological effects of these indigenous probiotic candidates to support their further development and future clinical investigation. Materials and methods Bacterial culture and biomass production L. helveticus DLBSA201 and DLBSA202 were acquired from Dexa Laboratories of Biomolecular Sciences (Indonesia). Draft genomes from both isolates have been submitted to GenBank with accession numbers NZ_WWEJ00000000 (DLBSA201) and NZ_WWEK00000000 (DLBSA202). Both isolates have also been securely preserved in the Indonesian Culture Collection (InaCC) for long-term confidential storage under controlled conditions, with registration numbers InaCC B 1643 and InaCC B 1644, respectively. Each isolate was revived separately in 30 mL MRS Broth medium (Merck, Germany) and incubated at 37 ℃ for 22 h. The inoculum was then gradually sub-cultured to produce inoculum for 10 L fermentation in a bioreactor (New Brunswick BioFlo 115) at 37 ℃ for 22 h. The cell pellets were obtained by centrifugation at 8000 rpm for 10 min at 4℃ (Hermle Z446K, Germany) and washed twice with 1 × sterile phosphate buffered saline. The cell pellet was suspended in a micro-encapsulant solution containing 23.53% (w/v) of maltodextrin and 17.65% (w/v) of whey protein isolate with a ratio of about 1:5. The suspension was then freeze-dried (Martin Christ Alpha 1–2 LD) at −60℃ for 2 days. The freeze-dried cultures were enumerated and kept at 4℃ before being used. For mixed culture, DLBSA201 and DLBSA202 were mixed with a ratio of 1:1. A 1:1 combination of DLBSA201 and DLBSA202 was used based on previous in vitro findings demonstrating improved probiotic efficacy of the mixed culture compared with individual strains [12]. Freeze-dried encapsulants with the same composition were used as a placebo. The cell suspensions for administration to the rats were prepared freshly prior to use by dissolving the freeze-dried culture in saline water to obtain the desired concentration. Animals Acute and sub-chronic oral toxicity studies were carried out in Wistar rats. All experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Dexa Laboratories of Biomolecular Sciences (DIS-DLBS-PROC−037 and DIS-DLBS-PROC−038) and conducted in accordance with 8th Edition of the Guide for the Care and Use of Laboratory Animals [18], the Regulation of the Indonesian Food and Drug Authority No. 7 of 2014, and in compliance with OECD Test Guidelines 420 [19] and 408 [20] for acute and repeated oral toxicity studies, respectively. The study was reported in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) 2.0 guidelines. Female Wistar rats used for the acute study were obtained from the Integrated Research and Testing Laboratory (LPPT), Gadjah Mada University, while male and female rats used for the sub-chronic study were sourced from in-house breeding. Animals used in the acute toxicity study were approximately 8–12 weeks old, while those used in the sub-chronic study were 6–8 weeks old, with individual body weights maintained within ± 20% of the mean for each experimental group. Each experiment included a control and multiple dose groups, conducted in a randomized parallel-group design. Animals were housed in polypropylene cages (Tecniplast 2154 F) of 480 mm× 265 mm x 210 mm in a room with a controlled environment at 20 – 26°C, 30 – 70% relative humidity and an alternating 12 h of light/dark cycle. For the acute toxicity study, animals were housed in groups of up to 2 rats per cage, allowing normal social interaction. For the sub-chronic study, animals were individually housed to ensure accurate monitoring of food consumption, clinical signs, and fecal samples. Environmental enrichment, including paper nesting materials and polycarbonate tunnels, was provided to promote animal welfare and natural behaviors. Rats were fed a standard laboratory diet containing 26.38% protein, 5.64% total fat, 50.76 Kcal/100 g energy from fat, 2.38% crude fiber, and 53.55% carbohydrate, with mineral drinking water provided ad libitum unless otherwise stated. All animals were acclimated for 7 days before the experiments. Animals showing abnormal behavior or weight deviations > 20% during acclimatization were excluded. Randomization was performed using simple random sampling. Personnel conducting clinical observations and histopathological evaluations were blinded to treatment allocation. The selected dose range was based on the anticipated human daily probiotic intake and was designed to include doses substantially higher than the expected human equivalent dose (HED, 10⁹ CFU/rat/day). Previous probiotic safety studies have similarly employed doses approximately 10–100 times (1010–10 ¹¹ CFU/rat/day) higher than the intended human consumption level to evaluate potential toxicological effects under exaggerated exposure conditions [21], [22], [23]. At the end of the study, all rats were euthanized using the exsanguination method under anesthesia. Anesthetization was carried out using ketamine at a dose of 80 mg/kg BW and xylazine at 10 mg/kg BW. Acute oral toxicity study After a 7-day acclimatization period, thirty-five female Wistar rats with a weight variation of ≤ 20% of the average body weight of all rats were randomly divided into 7 groups (Table 1). The rats were fasted for 15 h before and 3 h after administration of a single dose of probiotic or placebo. The observation started 30 min after the administration of test substance and was performed every 4 h periodically within the first 24 h, and continued daily until day−14. Observation included body weight (three times a week), signs of acute toxicity, changes in skin, fur, eyes, and mucous membranes, somatomotor activity, behavior pattern, tremors, convulsions, salivation, diarrhea, lethargy, sleep, and changes in gait. At day 14, rats were euthanized by exsanguination method after anesthesia, followed by observation of macropathology. Macroscopic observation of the heart, lungs, liver, spleen, adrenals, kidney, ovarian-uterine, gastric, and pancreas was conducted after the rats were euthanized. In addition, the relative organ weight of the heart, lung, liver, spleen, and kidney was examined and calculated as follows:Relativeorganweight%=weightoforganglivebodyweightg✕100Table 1Animal grouping for the acute oral toxicity study.Animal groupingTreatmentControlNormal/ placebo group - receive a normal diet + placebo suspensionLD DLBSA201Low Dose (LD) - receive a normal diet and probiotic DLBSA201 culture (∼2.5 ×1010 CFU/rat)MD DLBSA201Medium Dose (MD) - receive a normal diet and probiotic DLBSA201 culture (∼2.5 ×1011 CFU/rat)HD DLBSA201High Dose (MD) - receive a normal diet and probiotic DLBSA201 culture (∼5 ×1011 CFU/rat)LD DLBSA202Low Dose (LD) - receive a normal diet and probiotic DLBSA202 culture (∼2.5 ×1010 CFU/rat)MD DLBSA202Medium Dose (MD) - receive a normal diet and probiotic DLBSA202 culture (∼2.5 ×1011 CFU/rat)HD DLBSA202High Dose (MD) - receive a normal diet and probiotic DLBSA202 culture (∼5 ×1011 CFU/rat) Table 1Animal grouping for the acute oral toxicity study.Animal groupingTreatmentControlNormal/ placebo group - receive a normal diet + placebo suspensionLD DLBSA201Low Dose (LD) - receive a normal diet and probiotic DLBSA201 culture (∼2.5 ×1010 CFU/rat)MD DLBSA201Medium Dose (MD) - receive a normal diet and probiotic DLBSA201 culture (∼2.5 ×1011 CFU/rat)HD DLBSA201High Dose (MD) - receive a normal diet and probiotic DLBSA201 culture (∼5 ×1011 CFU/rat)LD DLBSA202Low Dose (LD) - receive a normal diet and probiotic DLBSA202 culture (∼2.5 ×1010 CFU/rat)MD DLBSA202Medium Dose (MD) - receive a normal diet and probiotic DLBSA202 culture (∼2.5 ×1011 CFU/rat)HD DLBSA202High Dose (MD) - receive a normal diet and probiotic DLBSA202 culture (∼5 ×1011 CFU/rat) Animal grouping for the acute oral toxicity study. Sub-chronic oral toxicity study Experimental design A total of 66 male and 66 female rats were randomly assigned to 6 groups after the acclimatization period was completed (Table 2). Each rat in the control group received 400 µL of placebo suspension, while treated rats received 400 µL of probiotics suspension at varying concentrations. Treatment was administered daily around 9:00 am for 90 consecutive days by oral gavage.Table 2Animal grouping for the sub-chronic oral toxicity study.Animal groupingTreatmentCSCNormal/ placebo group (CSC) - receive a normal diet + placebo suspension for 90 daysLD - SCLow Dose (LD - SC) - receive a normal diet and probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×109 CFU/rat/day) for 90 daysMD - SCMedium Dose (MD - SC) - receive a normal diet and probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×1010 CFU/rat/day) for 90 daysHD - SCHigh Dose (HD - SC) - receive a normal diet and probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×1011 CFU/rat/day) for 90 daysSSCSatellite normal/ placebo group (SSC) - receive a normal diet + placebo suspension for 90 days following 30 days of observationSHDSatellite High Dose (SHD) - receive a normal diet + probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×1011 CFU/rat/day) for 90 days following 30 days of observation Table 2Animal grouping for the sub-chronic oral toxicity study.Animal groupingTreatmentCSCNormal/ placebo group (CSC) - receive a normal diet + placebo suspension for 90 daysLD - SCLow Dose (LD - SC) - receive a normal diet and probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×109 CFU/rat/day) for 90 daysMD - SCMedium Dose (MD - SC) - receive a normal diet and probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×1010 CFU/rat/day) for 90 daysHD - SCHigh Dose (HD - SC) - receive a normal diet and probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×1011 CFU/rat/day) for 90 daysSSCSatellite normal/ placebo group (SSC) - receive a normal diet + placebo suspension for 90 days following 30 days of observationSHDSatellite High Dose (SHD) - receive a normal diet + probiotic mix of L. helveticus DLBSA201 & DLBSA202 culture (∼1 ×1011 CFU/rat/day) for 90 days following 30 days of observation Animal grouping for the sub-chronic oral toxicity study. General observations Observations were done about 60 min after rats received a daily dose of treatment for 90 days. The observation included toxic symptoms and clinical symptoms such as changes in the skin, hair, eyes, mucous membranes, secretions, excretions, changes in the way of walking, strange behavior (e.g., walking backward), seizures, mortality, and defecation (fecal consistency). Bodyweight and food consumption were weighed every three days using a digital balance (Sartorius Quintix 1102–1S). In satellite groups, observations were continued for 30 more days post-treatment to assess delayed or reversible toxic effects caused by the treatment substances. Gross pathology, relative organ weights, and histopathological analysis After exsanguination, organs consisting of the heart, lung, liver, spleen, kidney, pancreas, gastric, duodenum, jejunum, and colon of the animals were collected for analyses and gross pathological examinations. The heart, lung, liver, spleen, kidneys, and adrenals of each rat were weighed, and the relative organ weight was calculated using the following equation:Relativeorganweight%=weightoforganglivebodyweightg✕100 Histopathological examination was also performed on the kidney, intestine, heart, lung, liver, and spleen of all rats from all groups. Tissue organs were fixed in a 10% neutral buffered formalin (NBF) solution, embedded in paraffin wax, stained with hematoxylin and eosin, and then examined under a light microscope (Binocular microscope XSZ107BN). Histopathological examination was performed qualitatively to assess the presence or absence of tissue abnormalities. Serum biochemistry and hematological analysis At the end of the experiment, for hematological examination, blood was collected through a central vein of the tail and cardiac puncture after ensuring the animals were in a deep anesthetic state. The blood was collected in tubes containing EDTA and analyzed for hemoglobin (HGB), red blood cell (RBC), white blood cell (WBC), hematocrit (HCT), thrombocytes (PLT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) using an automated hematology analyzer (Nihon Kohden MEK-6450K). The manual differential was carried out to identify changes in the appearance of white blood cells, such as neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), and basophils (BAS). The results of the white blood cell differential are reported as percentages and absolute values. To investigate the toxic effects in tissues, specifically the kidney and liver, blood was collected in plain tubes for serum biochemistry analysis. Blood serum was obtained by allowing blood to clot at room temperature for 45 min, followed by centrifugation at 1000–2000 g for 15 min. The supernatant, containing serum, was then collected and immediately stored at −80°C for subsequent analysis [24]. The serum biochemistry analysis of total cholesterol (TC), triglycerides (TG), blood urea nitrogen (BUN), creatinine (Crea), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) was analyzed using an automatic veterinary clinical chemistry analyzer (Exigo C200, Boule). Meanwhile, the blood glucose (GLU) evaluation was performed with a glucometer using fresh blood obtained before anesthesia by performing a tail tip puncture. Animals were fasted overnight before blood sampling to prevent data bias. Bacterial translocation ability and bacteremia The ability of DLBSA201 and DLBSA202 to translocate to the heart, lung, kidney, intestine, spleen, and liver, three random rats from each sex in all groups were excised aseptically and collected in a tube containing 5 mL of MRS Broth (Merck) before being plated on MRS Agar (Merck). For bacteremia detection, a total of 50 μL portion of the blood of the rats was added to sterile tubes containing 450 μL of sterile saline and was directly plated on MRS Agar. Microbiological analysis of fecal content and colon swab Fecal samples were collected from five male rats and analyzed for Lactobacillus (Rogosa Agar, Merck Germany), total lactic acid bacteria (MRS Agar, Merck Germany), total aerobic bacteria (Soybean-Casein Digest Agar, Merck Germany), Presumptive Salmonella (Xylose Lysine Deoxycholate Agar, Oxoid UK), and E. coli (MacConkey Agar, Oxoid UK). For fecal content analysis, 1 g of fecal content was suspended in 9 mL of sterile PBS and vortexed for 1 min. After serial dilutions in buffer peptone (Merck, Germany), samples were added to appropriate selective agar media for enumeration. Plates were incubated for 48 h at 37 ℃ in aerobic conditions for lactobacilli, 48 h at 35℃ in aerobic conditions for Salmonella, E. coli, and total aerobic bacteria. The microbial population was expressed as log CFU/g fecal content. Prior to euthanasia at the end of the study, a colon swab test was conducted to analyze the Lactobacillus spp population within the colon. The total number of colonies from both experiments was compared between groups. Detection of Lactobacillus helveticus using polymerase chain reaction (PCR) The DNA of L. helveticus present in the fecal samples was isolated using Quick-DNA™ Fecal/Soil Microbe Miniprep Kit (Zymo Research, USA) according to the manufacturer’s instructions. The DNA obtained for this experiment was isolated from 1 g of rat fecal samples. The DNA was dissolved in the same amount of DNA elution buffer and stored at −20℃ before further use. The primers used in this study were LH_F: 5’-ATCAGCTGGGCCATTACCTT−3’ and LH_R: 5’-GATTGCTTCTGGGACCGATG−3’. The DNA was amplified with the following procedure: initial denaturation (95℃, 2 min), denaturation (95℃, 20 s), annealing (60℃, 30 s), extension (72℃, 30 s), and final extension (72℃, 5 min) for 30 cycles. Amplification results were then subjected to electrophoresis in 1% (w/v) agarose gels in the 1 × TAE buffer and visualized under UV light. The band intensity was calculated using ImageJ software. Harmful intestinal bacterial enzyme assay Detection of harmful bacteria enzymes was performed at the end of the study. Briefly, 1 g of fresh cecal content was suspended in 10 mL PBS (pH 7.2) and then centrifuged at 3000 × g for 5 min at room temperature. The supernatant was used to determine β-glucosidase activity and β-glucuronidase activity using a kit (Bio Rad, USA). Statistical analysis The LD50 values in the acute oral toxicity study were determined by the methods of Thompson & Weil, Litchfield & Wilcoxon, Miller & Tainter, linear/probit regression, or other statistical methods followed by post hoc test for multiple comparisons (Tukey's HSD or Games-Howell test) using SPSS® 23 Statistic software (Statistical Package for the Social Sciences; SPSS Inc., Chicago, IL, USA. All data in this study were expressed as mean ± SD. All statistical tests were done at 5% significance level. Results Acute oral toxicity The single-dose oral acute toxicity study of DLBSA201 and DLBSA202 at three different doses (∼2.5 ×1010 CFU/rat, ∼2.5 ×1011 CFU/rat, or ∼5 ×1011 CFU/rat) showed no mortality and toxicity signs throughout the experimental period. Further, there were no significant changes in body weight gain (Fig. 1A) and relative organ weight between the control group and the treatment group (Fig. 1B). No gross pathological changes were found when organs in all rats were observed at necropsy (Fig. 1C). Therefore, no histopathological examination was conducted.Fig. 1Acute oral toxicity study of L. helveticus DLBSA201 dan DLBSA202. (A) Body weight, (B) Relative organ weight, (C) Macroscopic observation of organs. Acute oral toxicity study of L. helveticus DLBSA201 dan DLBSA202. (A) Body weight, (B) Relative organ weight, (C) Macroscopic observation of organs. Sub-chronic oral toxicity study General observations The administration of the mixture of DLBSA201 and DLBSA202 for 90 consecutive days did not cause any mortality or toxicity signs such as tremors, seizures, salivation, diarrhea, lethargy, or weaknesses in daily observation. In addition, no alteration was found in the appearance and behavior of all rats in all groups in the sub-chronic oral toxicity study. Body weight and feed consumption The rat’s body weight gradually increased by the day of the study, but the body weight gain was not significantly different between the control and treatment groups (p > 0.05) (Fig. 2).Fig. 2Body weight male (A) and female (B); Feed consumption of male (C) and female (D) rats during sub-chronic oral toxicity study. Body weight male (A) and female (B); Feed consumption of male (C) and female (D) rats during sub-chronic oral toxicity study. Feed consumption in male rats was higher than in female rats throughout the experimental period (Fig. 2). The feed consumption of male rats was 60 – 80 g per 3 days, while the feed consumption of female rats was 40 – 60 g per 3 days. Given the data, there were no significant differences (p > 0.05) between control and treatment groups in both male and female rats. Gross pathology, relative organ weights, and histopathological analysis The relative organ weights of heart, lung, liver, spleen, kidney, and adrenal glands for both male and female rats were not significantly different (p > 0.05) between the control and all treated groups (Table 3 and Table 4 for male and female rats, respectively). Examination of the selected organs following the autopsy did not find any noticeable pathological changes. Moreover, histopathological analysis also did not show any changes or abnormalities in male and female rats when organs from the control group were compared to the treatment groups (Fig. 3, Fig. 4, Fig. 5, Fig. 6, Fig. 7, Fig. 8). No necrosis, fibrosis, or inflammation was detected in any of the examined organs of both male and female rats in all groups. For instance, lungs in all groups showed normal bronchioles, alveolar ducts, and alveolar sacs. Cardiac muscle and elastic fibers in the heart were arranged in an orderly manner. Further, it also showed normal myocardial syncytial muscle fibers with the heart's normal arrangement, nuclei, and vasculature. Normal histological structure of the central vein and surrounding hepatocytes in the liver was also found in rats in all groups. Hepatocytes appeared in rows separated by hepatic sinusoids, and some of the Kupffer cells were presented. Necrosis was not detected in the hepatocytes. Spleen microscopy from all groups showed normal white and red pulp. Kidneys of the control and treatment groups showed a normal histological picture and normal glomerulus.Table 3Relative organ weights (%) of male rats.OrganCSC(n = 11)LD - SC (n = 11)MD - SC (n = 11)HD - SC (n = 11)SSC(n = 10)SHD(n = 11)Liver3.12 ± 0.152.96 ± 0.272.88 ± 0.202.92 ± 0.222.73 ± 0.242.74 ± 0.32Lungs0.40 ± 0.110.39 ± 0.060.38 ± 0.080.39 ± 0.060.37 ± 0.060.37 ± 0.05Heart0.28 ± 0.020.30 ± 0.020.30 ± 0.020.29 ± 0.010.29 ± 0.010.28 ± 0.02Spleen0.19 ± 0.010.20 ± 0.020.20 ± 0.020.19 ± 0.020.18 ± 0.010.18 ± 0.02Left Kidney0.30 ± 0.010.34 ± 0.050.33 ± 0.030.31 ± 0.020.31 ± 0.030.30 ± 0.02Right Kidney0.31 ± 0.020.34 ± 0.040.33 ± 0.020.31 ± 0.020.31 ± 0.030.31 ± 0.03Left Adrenal Glands0.003 ± 0.0010.003 ± 0.0010.004 ± 0.0010.003 ± 0.0010.003 ± 0.0010.003 ± 0.001Right Adrenal Glands0.003 ± 0.0010.003 ± 0.0010.004 ± 0.0010.003 ± 0.0020.003 ± 0.0010.003 ± 0.001Table 4Relative organ weights (%) of female rats.OrganCSC(n = 11)LD - SC (n = 11)MD - SC (n = 11)HD - SC (n = 11)SSC(n = 11)SHD(n = 11)Liver2.97 ± 0.093.05 ± 0.202.95 ± 0.163.15 ± 0.302.69 ± 0.372.89 ± 0.26Lungs0.42 ± 0.040.48 ± 0.060.46 ± 0.030.47 ± 0.080.47 ± 0.080.45 ± 0.02Heart0.32 ± 0.020.34 ± 0.010.34 ± 0.020.34 ± 0.040.33 ± 0.030.33 ± 0.03Spleen0.24 ± 0.010.24 ± 0.020.24 ± 0.020.26 ± 0.020.23 ± 0.030.23 ± 0.02Left Kidney0.30 ± 0.020.35 ± 0.020.32 ± 0.020.30 ± 0.030.33 ± 0.050.33 ± 0.02Right Kidney0.30 ± 0.020.36 ± 0.020.33 ± 0.020.31 ± 0.020.33 ± 0.050.32 ± 0.02Left Adrenal Glands0.005 ± 0.0020.008 ± 0.0030.009 ± 0.0020.005 ± 0.0020.005 ± 0.0020.006 ± 0.002Right Adrenal Glands0.005 ± 0.0020.008 ± 0.0030.008 ± 0.0020.005 ± 0.0020.006 ± 0.0020.006 ± 0.002Fig. 3Histopathology image of rat’s lungs fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose.Fig. 4Histopathology image of rat’s heart fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose.Fig. 5Histopathology image of rat’s liver fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose.Fig. 6Histopathology image of rat’s spleen fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose.Fig. 7Histopathology image of rat’s kidney fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose.Fig. 8Histopathology image of rat’s intestine fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Table 3Relative organ weights (%) of male rats.OrganCSC(n = 11)LD - SC (n = 11)MD - SC (n = 11)HD - SC (n = 11)SSC(n = 10)SHD(n = 11)Liver3.12 ± 0.152.96 ± 0.272.88 ± 0.202.92 ± 0.222.73 ± 0.242.74 ± 0.32Lungs0.40 ± 0.110.39 ± 0.060.38 ± 0.080.39 ± 0.060.37 ± 0.060.37 ± 0.05Heart0.28 ± 0.020.30 ± 0.020.30 ± 0.020.29 ± 0.010.29 ± 0.010.28 ± 0.02Spleen0.19 ± 0.010.20 ± 0.020.20 ± 0.020.19 ± 0.020.18 ± 0.010.18 ± 0.02Left Kidney0.30 ± 0.010.34 ± 0.050.33 ± 0.030.31 ± 0.020.31 ± 0.030.30 ± 0.02Right Kidney0.31 ± 0.020.34 ± 0.040.33 ± 0.020.31 ± 0.020.31 ± 0.030.31 ± 0.03Left Adrenal Glands0.003 ± 0.0010.003 ± 0.0010.004 ± 0.0010.003 ± 0.0010.003 ± 0.0010.003 ± 0.001Right Adrenal Glands0.003 ± 0.0010.003 ± 0.0010.004 ± 0.0010.003 ± 0.0020.003 ± 0.0010.003 ± 0.001 Relative organ weights (%) of male rats. Table 4Relative organ weights (%) of female rats.OrganCSC(n = 11)LD - SC (n = 11)MD - SC (n = 11)HD - SC (n = 11)SSC(n = 11)SHD(n = 11)Liver2.97 ± 0.093.05 ± 0.202.95 ± 0.163.15 ± 0.302.69 ± 0.372.89 ± 0.26Lungs0.42 ± 0.040.48 ± 0.060.46 ± 0.030.47 ± 0.080.47 ± 0.080.45 ± 0.02Heart0.32 ± 0.020.34 ± 0.010.34 ± 0.020.34 ± 0.040.33 ± 0.030.33 ± 0.03Spleen0.24 ± 0.010.24 ± 0.020.24 ± 0.020.26 ± 0.020.23 ± 0.030.23 ± 0.02Left Kidney0.30 ± 0.020.35 ± 0.020.32 ± 0.020.30 ± 0.030.33 ± 0.050.33 ± 0.02Right Kidney0.30 ± 0.020.36 ± 0.020.33 ± 0.020.31 ± 0.020.33 ± 0.050.32 ± 0.02Left Adrenal Glands0.005 ± 0.0020.008 ± 0.0030.009 ± 0.0020.005 ± 0.0020.005 ± 0.0020.006 ± 0.002Right Adrenal Glands0.005 ± 0.0020.008 ± 0.0030.008 ± 0.0020.005 ± 0.0020.006 ± 0.0020.006 ± 0.002 Relative organ weights (%) of female rats. Histopathology image of rat’s lungs fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Histopathology image of rat’s heart fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Histopathology image of rat’s liver fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Histopathology image of rat’s spleen fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Histopathology image of rat’s kidney fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Histopathology image of rat’s intestine fed with mixture of L. helveticus DLBSA201 and DLBSA202 (HE, 40x magnification). CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Serum biochemistry and hematological analysis Serum biochemistry analysis There were no significant differences between control and treated groups of all serum biochemistry parameters (AST, ALT, Crea, TC, TG, GLU) in male rats except for blood urea nitrogen (Table 5). The BUN levels of the treated groups were slightly lower than the control group, especially in the low dose group (Table 5). Meanwhile, there were significant differences between the control and treated groups in some biochemistry parameters, such as ALT, TC, TG, and BUN of female rats (Table 6). This phenomenon did not occur in a dose-dependent manner. In short, the significant differences were most likely caused by the variety between individuals and not caused by the test substances.Table 5Serum biochemistry analysis of male rat.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 10)SHD(n = 11)AST (U/l)114.27 ± 45.70123.91 ± 41.00127.80 ± 26.68110.64 ± 26.17107.60 ± 27.90126.09 ± 40.62ALT (U/l)74.27 ± 17.0471.18 ± 10.9573.80 ± 10.9381.55 ± 11.0276.20 ± 19.8976.91 ± 16.53Crea (mg/dl)0.20 ± 0.080.21 ± 0.100.16 ± 0.110.35 ± 0.120.24 ± 0.120.16 ± 0.08TC (mg/dl)81.13 ± 12.0468.04 ± 7.9774.77 ± 6.8985.64 ± 13.5578.69 ± 13.2580.92 ± 8.73TG (mg/dl)53.61 ± 26.3728.28 ± 6.6730.16 ± 0.0240.33 ± 15.7934.17 ± 18.3246.17 ± 23.27GLU (mg/dl)100.82 ± 13.95112.73 ± 7.31108.70 ± 8.86101.45 ± 5.35105.50 ± 11.22104.64 ± 11.03BUN (mg/dl)27.22 ± 5.7419.51 ± 2.78a20.66 ± 2.75a23.49 ± 3.4719.46 ± 5.38a18.19 ± 2.75aNote: a: p < 0.05 compared to control groupTable 6Serum biochemistry analysis of female rats.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 11)SHD(n = 11)AST (U/l)114.82 ± 24.09145 ± 43.24118.18 ± 25.25140.27 ± 50.4496.27 ± 7.91105.27 ± 21.24ALT (U/l)96.55 ± 15.1861.27 ± 14.16a57.55 ± 9.35a85.00 ± 10.2771.00 ± 13.30a70.73 ± 11.59aCrea (mg/dl)0.26 ± 0.100.26 ± 0.150.22 ± 0.130.21 ± 0.120.31 ± 0.090.25 ± 0.20TC (mg/dl)83.44 ± 9.7561.84 ± 19.24ab76.23 ± 6.2079.1 ± 8.2285.89 ± 22.3888.20 ± 23.91TG (mg/dl)76.96 ± 32.3332.93 ± 16.93a26.99 ± 8.67a55.60 ± 16.7831.84 ± 14.53a29.05 ± 26.12aGLU (mg/dl)95.18 ± 6.3185.45 ± 5.48a94.00 ± 9.4799.64 ± 6.1296.64 ± 8.1495.91 ± 7.12BUN (mg/dl)25.47 ± 3.4720.14 ± 3.16a22.22 ± 2.5427.34 ± 4.5721.19 ± 2.3721.60 ± 3.63Note: a: p < 0.05 compared to control group Table 5Serum biochemistry analysis of male rat.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 10)SHD(n = 11)AST (U/l)114.27 ± 45.70123.91 ± 41.00127.80 ± 26.68110.64 ± 26.17107.60 ± 27.90126.09 ± 40.62ALT (U/l)74.27 ± 17.0471.18 ± 10.9573.80 ± 10.9381.55 ± 11.0276.20 ± 19.8976.91 ± 16.53Crea (mg/dl)0.20 ± 0.080.21 ± 0.100.16 ± 0.110.35 ± 0.120.24 ± 0.120.16 ± 0.08TC (mg/dl)81.13 ± 12.0468.04 ± 7.9774.77 ± 6.8985.64 ± 13.5578.69 ± 13.2580.92 ± 8.73TG (mg/dl)53.61 ± 26.3728.28 ± 6.6730.16 ± 0.0240.33 ± 15.7934.17 ± 18.3246.17 ± 23.27GLU (mg/dl)100.82 ± 13.95112.73 ± 7.31108.70 ± 8.86101.45 ± 5.35105.50 ± 11.22104.64 ± 11.03BUN (mg/dl)27.22 ± 5.7419.51 ± 2.78a20.66 ± 2.75a23.49 ± 3.4719.46 ± 5.38a18.19 ± 2.75aNote: a: p < 0.05 compared to control group Serum biochemistry analysis of male rat. Note: a: p < 0.05 compared to control group Table 6Serum biochemistry analysis of female rats.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 11)SHD(n = 11)AST (U/l)114.82 ± 24.09145 ± 43.24118.18 ± 25.25140.27 ± 50.4496.27 ± 7.91105.27 ± 21.24ALT (U/l)96.55 ± 15.1861.27 ± 14.16a57.55 ± 9.35a85.00 ± 10.2771.00 ± 13.30a70.73 ± 11.59aCrea (mg/dl)0.26 ± 0.100.26 ± 0.150.22 ± 0.130.21 ± 0.120.31 ± 0.090.25 ± 0.20TC (mg/dl)83.44 ± 9.7561.84 ± 19.24ab76.23 ± 6.2079.1 ± 8.2285.89 ± 22.3888.20 ± 23.91TG (mg/dl)76.96 ± 32.3332.93 ± 16.93a26.99 ± 8.67a55.60 ± 16.7831.84 ± 14.53a29.05 ± 26.12aGLU (mg/dl)95.18 ± 6.3185.45 ± 5.48a94.00 ± 9.4799.64 ± 6.1296.64 ± 8.1495.91 ± 7.12BUN (mg/dl)25.47 ± 3.4720.14 ± 3.16a22.22 ± 2.5427.34 ± 4.5721.19 ± 2.3721.60 ± 3.63Note: a: p < 0.05 compared to control group Serum biochemistry analysis of female rats. Note: a: p < 0.05 compared to control group Hematological analyses In general, all parameters of hematological analysis of both male and female rats across all groups did not differ significantly (p > 0.05). RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEU, LYM, MON, EOS, and BAS levels were comparable between control and treated groups in male and female rats (Table 7, Table 8). However, the WBC count of female rats in the HD-SC group was significantly higher (p < 0.05) compared to the control group. The increase in WBC count in the HD group of female rats was not dose-dependent, as the WBC count in the medium dose group was slightly lower than that in the control and medium dose groups. In addition, the increase in WBC in the high-dose group of female rats was not observed in the high-dose satellite group. This result suggested that the increase in WBC count could be reversible or caused by variation between individuals.Table 7Hematology analysis results of male rats.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 10)SHD(n = 11)WBC (103/µl)9.65 ± 1.229.05 ± 1.848.28 ± 1.689.51 ± 0.928.37 ± 1.639.98 ± 2.65RBC (106/µl)8.75 ± 0.378.38 ± 0.438.71 ± 0.448.71 ± 0.408.78 ± 0.328.47 ± 0.44HGB (g/dl)15.53 ± 0.6515.78 ± 0.3415.70 ± 0.7015.58 ± 0.6014.38 ± 0.5215.50 ± 0.62HCT (%)45.11 ± 1.9145.95 ± 1.7945.53 ± 2.4246.12 ± 1.7642.07 ± 1.8544.99 ± 1.56MCV (fL)51.58 ± 0.8254.89 ± 1.1252.29 ± 1.1252.98 ± 1.1047.82 ± 0.7753.23 ± 2.10bMCH (pg)17.75 ± 0.4518.87 ± 0.7418.02 ± 0.3517.91 ± 0.4216.37 ± 0.3718.33 ± 0.45bMCHC (g/dl)34.42 ± 0.5034.37 ± 0.9234.49 ± 0.5533.78 ± 0.5531.14 ± 0.7334.45 ± 0.91bPLT (103/µl)838.27 ± 62.96803.45 ± 44.36855.55 ± 64.51820.00 ± 56.60774.46 ± 44.88826.09 ± 67.36NEU (%)15.09 ± 9.8322.63 ± 5.5924.54 ± 10.0418.60 ± 7.5718.56 ± 2.1018.63 ± 7.26NEU (103/µl)1.50 ± 1.202.08 ± 0.812.05 ± 0.932.32 ± 1.351.57 ± 0.341.87 ± 1.03LYM (%)80.45 ± 9.8974.81 ± 6.2373.64 ± 10.5578.80 ± 7.6671.86 ± 2.5079.73 ± 7.55LYM (103/µl)7.72 ± 1.116.73 ± 1.286.08 ± 1.439.30 ± 0.746.32 ± 1.277.93 ± 1.94MON (%)4.18 ± 2.862.73 ± 2.152.73 ± 2.153.00 ± 1.411.95 ± 1.451.90 ± 1.45MON (103/µl)0.40 ± 0.290.26 ± 0.200.21 ± 0.180.37 ± 0.190.17 ± 0.130.21 ± 0.19EOS (%)0.36 ± 0.67000.40 ± 0.8900.18 ± 0.60EOS (103/µl)0.04 ± 0.07000.04 ± 0.1900.02 ± 0.07BAS (%)000000BAS (103/µl)000000Note: a: p < 0.05 compared to control group, b: p < 0.05 compared to satellite control groupTable 8Hematology analysis results of female rats.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 11)SHD(n = 11)WBC (103/µl)6.80 ± 1.126.65 ± 1.125.77 ± 1.228.83 ± 1.52a6.38 ± 1.776.17 ± 0.73RBC (106/µl)7.84 ± 0.367.84 ± 0.368.17 ± 0.267.78 ± 0.258.06 ± 0.307.99 ± 0.39HGB (g/dl)15.09 ± 0.3815.09 ± 0.3815.47 ± 0.5114.87 ± 0.4515.46 ± 0.5715.28 ± 0.65HCT (%)42.95 ± 0.8244.07 ± 1.8944.23 ± 1.6443.05 ± 1.4445.12 ± 1.2044.30 ± 1.52MCV (fL)54.43 ± 1.1655.70 ± 2.1754.12 ± 1.2755.31 ± 1.3056.01 ± 1.6655.48 ± 1.54MCH (pg)19.15 ± 0.4619.45 ± 0.8118.94 ± 0.6219.13 ± 0.4019.19 ± 0.4719.13 ± 0.45MCHC (g/dl)35.13 ± 0.4935.19 ± 1.1835.01 ± 0.8634.55 ± 0.4434.26 ± 1.1634.51 ± 1.01PLT (103/µl)769.91 ± 120.36839.30 ± 125.31803.00 ± 76.32834.82 ± 64.43814.82 ± 58.42796.70 ± 69.38NEU (%)11.00 ± 4.3614.77 ± 3.8817.27 ± 11.0312.55 ± 5.3415.55 ± 0.4714.27 ± 7.36NEU (103/µl)0.76 ± 0.350.96 ± 0.230.99 ± 0.711.15 ± 0.670.94 ± 0.390.86 ± 0.41LYM (%)87.36 ± 4.6183.5 ± 4.9282.64 ± 11.1282.64 ± 5.4680.64 ± 14.6984.55 ± 7.84LYM (103/µl)5.93 ± 0.955.58 ± 1.144.78 ± 1.227.25 ± 1.005.22 ± 1.915.24 ± 0.95MON (%)1.55 ± 1.211.91 ± 1.580.36 ± 0.505.00 ± 1.611.27 ± 1.271.27 ± 1.49MON (103/µl)0.10 ± 0.090.12 ± 0.090.02 ± 0.030.45 ± 0.170.08 ± 0.100.08 ± 0.09EOS (%)0.18 ± 0.4000000EOS (103/µl)0.12 ± 0.0300000BAS (%)000000BAS (103/µl)000000Note: a: p < 0.05 compared to control group; b: p < 0.05 compared to satellite control group Table 7Hematology analysis results of male rats.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 10)SHD(n = 11)WBC (103/µl)9.65 ± 1.229.05 ± 1.848.28 ± 1.689.51 ± 0.928.37 ± 1.639.98 ± 2.65RBC (106/µl)8.75 ± 0.378.38 ± 0.438.71 ± 0.448.71 ± 0.408.78 ± 0.328.47 ± 0.44HGB (g/dl)15.53 ± 0.6515.78 ± 0.3415.70 ± 0.7015.58 ± 0.6014.38 ± 0.5215.50 ± 0.62HCT (%)45.11 ± 1.9145.95 ± 1.7945.53 ± 2.4246.12 ± 1.7642.07 ± 1.8544.99 ± 1.56MCV (fL)51.58 ± 0.8254.89 ± 1.1252.29 ± 1.1252.98 ± 1.1047.82 ± 0.7753.23 ± 2.10bMCH (pg)17.75 ± 0.4518.87 ± 0.7418.02 ± 0.3517.91 ± 0.4216.37 ± 0.3718.33 ± 0.45bMCHC (g/dl)34.42 ± 0.5034.37 ± 0.9234.49 ± 0.5533.78 ± 0.5531.14 ± 0.7334.45 ± 0.91bPLT (103/µl)838.27 ± 62.96803.45 ± 44.36855.55 ± 64.51820.00 ± 56.60774.46 ± 44.88826.09 ± 67.36NEU (%)15.09 ± 9.8322.63 ± 5.5924.54 ± 10.0418.60 ± 7.5718.56 ± 2.1018.63 ± 7.26NEU (103/µl)1.50 ± 1.202.08 ± 0.812.05 ± 0.932.32 ± 1.351.57 ± 0.341.87 ± 1.03LYM (%)80.45 ± 9.8974.81 ± 6.2373.64 ± 10.5578.80 ± 7.6671.86 ± 2.5079.73 ± 7.55LYM (103/µl)7.72 ± 1.116.73 ± 1.286.08 ± 1.439.30 ± 0.746.32 ± 1.277.93 ± 1.94MON (%)4.18 ± 2.862.73 ± 2.152.73 ± 2.153.00 ± 1.411.95 ± 1.451.90 ± 1.45MON (103/µl)0.40 ± 0.290.26 ± 0.200.21 ± 0.180.37 ± 0.190.17 ± 0.130.21 ± 0.19EOS (%)0.36 ± 0.67000.40 ± 0.8900.18 ± 0.60EOS (103/µl)0.04 ± 0.07000.04 ± 0.1900.02 ± 0.07BAS (%)000000BAS (103/µl)000000Note: a: p < 0.05 compared to control group, b: p < 0.05 compared to satellite control group Hematology analysis results of male rats. Note: a: p < 0.05 compared to control group, b: p < 0.05 compared to satellite control group Table 8Hematology analysis results of female rats.ParameterCSC(n = 11)LD - SC(n = 11)MD - SC (n = 11)HD - SC(n = 11)SSC(n = 11)SHD(n = 11)WBC (103/µl)6.80 ± 1.126.65 ± 1.125.77 ± 1.228.83 ± 1.52a6.38 ± 1.776.17 ± 0.73RBC (106/µl)7.84 ± 0.367.84 ± 0.368.17 ± 0.267.78 ± 0.258.06 ± 0.307.99 ± 0.39HGB (g/dl)15.09 ± 0.3815.09 ± 0.3815.47 ± 0.5114.87 ± 0.4515.46 ± 0.5715.28 ± 0.65HCT (%)42.95 ± 0.8244.07 ± 1.8944.23 ± 1.6443.05 ± 1.4445.12 ± 1.2044.30 ± 1.52MCV (fL)54.43 ± 1.1655.70 ± 2.1754.12 ± 1.2755.31 ± 1.3056.01 ± 1.6655.48 ± 1.54MCH (pg)19.15 ± 0.4619.45 ± 0.8118.94 ± 0.6219.13 ± 0.4019.19 ± 0.4719.13 ± 0.45MCHC (g/dl)35.13 ± 0.4935.19 ± 1.1835.01 ± 0.8634.55 ± 0.4434.26 ± 1.1634.51 ± 1.01PLT (103/µl)769.91 ± 120.36839.30 ± 125.31803.00 ± 76.32834.82 ± 64.43814.82 ± 58.42796.70 ± 69.38NEU (%)11.00 ± 4.3614.77 ± 3.8817.27 ± 11.0312.55 ± 5.3415.55 ± 0.4714.27 ± 7.36NEU (103/µl)0.76 ± 0.350.96 ± 0.230.99 ± 0.711.15 ± 0.670.94 ± 0.390.86 ± 0.41LYM (%)87.36 ± 4.6183.5 ± 4.9282.64 ± 11.1282.64 ± 5.4680.64 ± 14.6984.55 ± 7.84LYM (103/µl)5.93 ± 0.955.58 ± 1.144.78 ± 1.227.25 ± 1.005.22 ± 1.915.24 ± 0.95MON (%)1.55 ± 1.211.91 ± 1.580.36 ± 0.505.00 ± 1.611.27 ± 1.271.27 ± 1.49MON (103/µl)0.10 ± 0.090.12 ± 0.090.02 ± 0.030.45 ± 0.170.08 ± 0.100.08 ± 0.09EOS (%)0.18 ± 0.4000000EOS (103/µl)0.12 ± 0.0300000BAS (%)000000BAS (103/µl)000000Note: a: p < 0.05 compared to control group; b: p < 0.05 compared to satellite control group Hematology analysis results of female rats. Note: a: p < 0.05 compared to control group; b: p < 0.05 compared to satellite control group Bacterial translocation ability and bacteremia No viable bacteria were obtained from tissue samples (heart, lung, kidney, intestine, spleen, and liver) of three random rats from each group. This result indicated that DLBSA201 and DLBSA202 are not able to translocate from the intestine to organs. Additionally, the blood samples also did not possess any bacteria. Thus, this result suggests that DLBSA201 and DLBSA202 have no ability to cause bacteremia. Microbiological analysis of fecal content and colon swab Low doses of DLBSA201 and DLBSA202 significantly reduced the number of total aerobic bacteria, E. coli, and Salmonella sp. At the same time, medium doses of DLBSA201 and DLBSA202 significantly increased the number of total lactic acid bacteria while significantly reducing the number of total aerobic bacteria and presumptive Salmonella sp. (Table 9). Furthermore, Lactobacillus sp. and total lactic acid bacteria were remarkably increased in the high-dose probiotic-treated group. Treatment with probiotics in the high-dose group also reduced the number of total aerobic bacteria, E. coli, and Salmonella sp. (Table 9). Similar to the fecal content analysis results, probiotic treatment at low, medium, and high doses tended to increase the number of Lactobacillus sp. and total LAB despite no significant difference was found (Table 10).Table 9Populations of several gut microbiota in fecal samples of control, low dose, medium dose, and high dose group during sub-chronic oral toxicity study.Bacterial population (in log CFU/g feces)DayCSC (n = 5)LD - SC (n = 5)MD - SC (n = 5)HD - SC (n = 5)MeanMinMaxMeanMinMaxMeanMinMaxMeanMinMaxLactobacillus spD−09.058.909.298.878.529.068.587.929.118.888.319.17D−908.08*7.459.119.09*8.729.228.948.499.229.46*8.8410.29Total LABD−09.519.0810.228.998.819.188.628.279.168.888.319.17D−908.80*8.219.279.048.089.348.89*8.369.299.58*8.7810.25Total aerobic bacteriaD−09.188.239.949.219.089.619.258.5310.489.429.259.79D−908.507.969.249.01*8.829.278.80*8.389.398.01*7.648.61Escherichia coliD−07.707.188.097.717.088.558.916.7010.038.197.958.37D−907.105.008.596.27*5.576.797.406.708.696.76*6.087.72Salmonella sp.D−04.553.485.386.395.536.826.545.567.536.074.437.27D−904.593.725.694.90*3.487.404.98*4.486.404.73*3.815.25Note: statistical analysis was conducted between two groups by student’s t-test. (*) indicating significant difference (p < 0.05) between D−0 and D−90Table 10Populations of Lactobacillus sp. and total lactic acid bacteria in colon swab samples.Bacterial population (in log CFU/g feces)CSC (n = 5)LD - SC (n = 5)MD - SC (n = 5)HD - SC (n = 5)MeanMinMaxMeanMinMaxMeanMinMaxMeanMinMaxLactobacillus sp4.854.005.825.445.005.704.784.395.395.314.306.75Total LAB4.974.305.565.775.006.485.204.616.005.864.706.82 Table 9Populations of several gut microbiota in fecal samples of control, low dose, medium dose, and high dose group during sub-chronic oral toxicity study.Bacterial population (in log CFU/g feces)DayCSC (n = 5)LD - SC (n = 5)MD - SC (n = 5)HD - SC (n = 5)MeanMinMaxMeanMinMaxMeanMinMaxMeanMinMaxLactobacillus spD−09.058.909.298.878.529.068.587.929.118.888.319.17D−908.08*7.459.119.09*8.729.228.948.499.229.46*8.8410.29Total LABD−09.519.0810.228.998.819.188.628.279.168.888.319.17D−908.80*8.219.279.048.089.348.89*8.369.299.58*8.7810.25Total aerobic bacteriaD−09.188.239.949.219.089.619.258.5310.489.429.259.79D−908.507.969.249.01*8.829.278.80*8.389.398.01*7.648.61Escherichia coliD−07.707.188.097.717.088.558.916.7010.038.197.958.37D−907.105.008.596.27*5.576.797.406.708.696.76*6.087.72Salmonella sp.D−04.553.485.386.395.536.826.545.567.536.074.437.27D−904.593.725.694.90*3.487.404.98*4.486.404.73*3.815.25Note: statistical analysis was conducted between two groups by student’s t-test. (*) indicating significant difference (p < 0.05) between D−0 and D−90 Populations of several gut microbiota in fecal samples of control, low dose, medium dose, and high dose group during sub-chronic oral toxicity study. Note: statistical analysis was conducted between two groups by student’s t-test. (*) indicating significant difference (p < 0.05) between D−0 and D−90 Table 10Populations of Lactobacillus sp. and total lactic acid bacteria in colon swab samples.Bacterial population (in log CFU/g feces)CSC (n = 5)LD - SC (n = 5)MD - SC (n = 5)HD - SC (n = 5)MeanMinMaxMeanMinMaxMeanMinMaxMeanMinMaxLactobacillus sp4.854.005.825.445.005.704.784.395.395.314.306.75Total LAB4.974.305.565.775.006.485.204.616.005.864.706.82 Populations of Lactobacillus sp. and total lactic acid bacteria in colon swab samples. To further investigate the availability of L. helveticus in fecal samples, we determined the level of L. helveticus by using a species-specific primer. The band intensity between D−0 and D−90 in all groups, including control, was compared using ImageJ software, and the band intensity of the control group at D−0 was used as the reference (intensity = 1.0). In D−90, all treatment groups (low, medium, and high dose) showed a tendency toward band intensity enhancement, up to 1.3 × compared to the control group at D−0, or 10–20% compared to D−0 in each group. These findings suggest a trend toward increased Lactobacillus helveticus detection in fecal samples after probiotic treatment (Fig. 9, p > 0.05).Fig. 9PCR band intensity of L. helveticus in fecal samples on D−0 and D−90. PCR band intensity of L. helveticus in fecal samples on D−0 and D−90. Harmful intestinal bacterial enzyme assay The results of the harmful cecal bacterial enzymes, β-glucosidase and β-glucuronidase, are shown in Fig. 10. The low dose group could not reduce the activity of the β-glucosidase and β-glucuronidase enzymes, while the medium-dose group only significantly decreased β-glucuronidase activity (p < 0.05). Furthermore, there was a significant reduction of β-glucosidase and β-glucuronidase enzyme activities in the high-dose group (p < 0.05).Fig. 10Harmful intestinal enzymes activity in rats treated with mixture of L. helveticus DLBSA201 and DLBSA202. CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Different letters (a-b or A-B) represent significant differences (p < 0.05) for the comparison between groups by one-way ANOVA. Harmful intestinal enzymes activity in rats treated with mixture of L. helveticus DLBSA201 and DLBSA202. CSC = control group (placebo), LD-SC = low dose (∼1 ×109 CFU/rat/day), MD-SC = medium dose (∼1 ×1010 CFU/rat/day), HD-SC = high dose (∼1 ×1011 CFU/rat/day), SSC = satellite control, SHD = satellite high dose. Different letters (a-b or A-B) represent significant differences (p < 0.05) for the comparison between groups by one-way ANOVA. Discussion Lactobacillus species are widely used in fermented foods and probiotic products because of their potential health-promoting properties. Among them, L. helveticus is assigned to the Qualified Presumption of Safety (QPS) group by the European Food Safety Authority (EFSA) guidelines [25]. While probiotics are generally considered safe, there have been reported cases of bacteremia, particularly in immunocompromised individuals [26]. A previous study highlighted the potential risks associated with probiotic therapy, especially in high-risk populations [27]. Cases of bacteremia linked to specific probiotic strains, such as Lactobacillus rhamnosus GG, have been documented, particularly in patients with weakened immune systems or those with indwelling medical devices [26]. Therefore, comprehensive preclinical evaluation is necessary before newly isolated strains are considered for further development. The present study evaluated the acute and sub-chronic oral toxicity of L. helveticus DLBSA201 and DLBSA202, as well as their effects on selected intestinal microbial populations and bacterial enzyme activity in Wistar rats. In the acute toxicity study, no mortality, abnormal clinical signs, behavioral alterations, body weight reduction, or gross pathological abnormalities were observed following oral administration of either strain at doses up to 5 × 10 ¹ ¹ CFU/rat. These findings suggest that both strains were well tolerated at the tested doses, with an estimated LD50 greater than 5 × 10 ¹ ¹ CFU/rat. Previous findings have also indicated that L. helveticus KLDS1.8701 [28], L. fermentum HM3 [14], and L. buchneri FD2 [14] exhibited no adverse effects, such as toxicity or behavioral abnormalities in rats following an acute toxicity study. Because acute toxicity studies alone are insufficient to establish the long-term safety profile of probiotics, a 90-day sub-chronic oral toxicity study was also performed. Repeated oral administration of the L. helveticus DLBSA201 and DLBSA202 mixture at doses ranging from 1 × 10⁹ to 1 × 10 ¹ ¹ CFU/rat/day did not produce treatment-related mortality, clinical toxicity, or gross pathological abnormalities. Based on the evaluated parameters, the NOAEL was considered to be 1 × 10 ¹ ¹ CFU/rat/day. Importantly, this probiotic mixture is considered practically safe for human consumption, as the suggested human dose for most probiotics ranges from 108−109 CFU [14], thereby supporting the preclinical safety profile of these strains. Body weight gain and feed consumption are important indicators commonly used in toxicity studies because substantial changes may reflect adverse physiological effects or reduced nutritional status [29], [30]. Moreover, a 10% decline in body weight is commonly used as a threshold to establish the maximum tolerated dose (MTD), the highest dose that produces clear signs of toxicity without causing death [29]. In the present study, no significant differences in body weight or feed consumption were observed between the treatment and control groups, and no reduction in body weight greater than 10% was detected. These findings suggest that administration of the probiotic mixture did not adversely affect normal growth or nutritional intake in the experimental animals. Similar observations have been reported in Spargue-Dawley as well as Wistar rats following the administration of L. plantarum LAB12, L. plantarum MF405176, L. fermentum MF033346, L. lactis subspecies lactis MF480428, E. faecium MF480431, and P. acidilactici MF480434 [30], [31]. Relative organ weight and histopathological examination provide additional insights into the potential toxic effects of drugs or chemicals by assessing organ weight changes and tissue damage following prolonged exposure to the test substance [32]. Throughout the experimental period, no significant treatment-related changes in organ weights were observed, and histopathological evaluation revealed no evidence of inflammation, necrosis, or structural abnormalities in the examined organs, including the liver, kidneys, spleen, heart, lungs, and intestines. These findings further support the absence of observable organ toxicity following repeated administration of the probiotic mixture. However, the histopathological evaluation in the present study was qualitative, and no standardized lesion grading or blinded semi-quantitative scoring system was applied. Hematological and serum biochemical analyses are important components of toxicological assessment because they provide information regarding systemic physiological and organ-related effects [33], [34]. Overall, the evaluated hematological parameters remained within normal physiological ranges and did not indicate treatment-related toxicity. Although a statistically significant increase in white blood cell (WBC) count was observed in the female high-dose group, the change was not dose dependent and was not accompanied by clinical signs, histopathological abnormalities, or evidence of systemic inflammation. Furthermore, the observed WBC values remained within the reported normal range for female Wistar rats [35], suggesting limited toxicological relevance. Similarly, several serum biochemical parameters, including triglycerides and total cholesterol, differed significantly between treated and control animals. However, these variations did not demonstrate a consistent dose-response relationship and were not associated with pathological alterations. Therefore, their toxicological significance remains unclear. Interestingly, probiotic-treated animals generally showed lower triglyceride and cholesterol levels compared with controls. These findings are consistent with previous reports describing potential lipid-modulating effects of certain Lactobacillus strains, including L. helveticus CD6 [36]. Previous in vitro findings also demonstrated cholesterol-lowering activity of L. helveticus DLBSA201 and DLBSA202 [37]. Nevertheless, the present study was not specifically designed to evaluate hypolipidemic effects, and therefore these observations should be interpreted cautiously. Satellite groups are commonly incorporated into sub-chronic toxicity studies to evaluate the persistence or reversibility of potential delayed toxic effects following treatment cessation [38]. All parameters evaluated in the satellite group to detect sub-chronic toxicity were within normal limits. Although significantly elevated MCV, MCH, and MCHC values were observed in male rats receiving the high dose, these values remained within the physiological reference range for male Wistar rats [39], suggesting that the observed differences were unlikely to represent toxicologically significant delayed effects. In recent years, there have been several reported cases of bacteremia and sepsis associated with probiotic use, especially among immunocompromised and hospitalized patients with severe illness [26]. L. gasseri, L. paracasei, and L. rhamnosus have been reported to cause bacteremia in immunocompromised individuals, including a 59-year-old diabetic man, an 8 months-old infant with hypoganglionosis, and an elderly woman with a past history of radiation enteritis [40], [41]. Considering the reported cases associated with Lactobacillus species, it is important to evaluate the translocation potential of probiotic strains prior to human consumption. In the present study, no detectable bacterial translocation to blood or internal organs was observed using culture-based methods following sub-chronic administration of L. helveticus DLBSA201 and DLBSA202. These findings suggest low translocation potential under the tested experimental conditions. However, it should be noted that the bacterial translocation assessment relied on culture-dependent methods, which may have limited sensitivity for detecting low-level translocation events. Modulation of gut microbiota composition is one of the principal mechanisms associated with probiotic activity. However, successful colonization and persistence of probiotic bacteria within the gastrointestinal tract remain challenging because both beneficial and pathogenic microorganisms compete for adhesion sites and nutrients [42], [43]. While some studies have shown that probiotics can increase certain bacterial groups, others have found less significant changes. For instance, a study by Rahayu showed comparable levels of total lactic acid bacteria between a placebo group and a group treated with L. plantarum Dad−13 [44]. Similarly, Li, et al. [28] observed no significant changes in Lactobacillus, Enterobacter, and Enterococcus levels in rats treated with a high dose of L. helveticus KDLS1.8701 [28]. In our study, probiotic administration tended to increase the populations of Lactobacillus spp. and total lactic acid bacteria in fecal samples. Although some dose groups did not show statistically significant differences, PCR analysis demonstrated increased detection of L. helveticus in fecal samples following treatment, suggesting survival of the administered strains during gastrointestinal transit. This observation is consistent with previous in vitro findings demonstrating the acid and bile tolerance of L. helveticus DLBSA201 and DLBSA202 [12]. However, the microbiological analysis in this study was limited to culture-based enumeration and PCR-based detection of selected bacteria. Therefore, the findings reflect only cultivable bacterial populations and do not represent the overall gut microbiome diversity or composition. Future studies using culture-independent approaches, such as 16S rRNA sequencing or metagenomic analysis, are needed to provide a more comprehensive understanding of microbiome modulation induced by L. helveticus DLBSA201 and DLBSA202. Another important consideration in probiotic safety evaluation is the potential influence of probiotic administration on bacterial enzymes such as β-glucosidase and β-glucuronidase, which are commonly associated with certain pathogenic intestinal bacteria [14]. Administration of L. helveticus DLBSA201 and DLBSA202 mixture was associated with the decreased of β-glucuronidase and β-glucosidase activity, particularly at higher doses. These findings were accompanied by reduced counts of total aerobic bacteria, Escherichia coli, and Salmonella spp., as well as increased populations of Lactobacillus spp. and total lactic acid bacteria. However, since mechanistic and metabolomic analyses were not conducted, the association between alterations in microbiota and enzyme activity should be interpreted as a correlation rather than a direct cause-and-effect relationship. Nevertheless, the findings suggest that L. helveticus DLBSA201 and DLBSA202 may have potential as probiotic candidates and warrant further investigation. Conclusion Oral administration of L. helveticus DLBSA201 and DLBSA202 at doses up to 5 × 10 ¹ ¹ CFU/day in acute and 90-day sub-chronic toxicity studies was generally well tolerated in Wistar rats under the conditions of this study, with no observed treatment-related adverse effects, mortality, or gross pathological abnormalities. No detectable bacterial translocation to organs or blood was observed using culture-based methods. In addition, probiotic administration was associated with reduced fecal populations of selected pathogenic bacteria and decreased bacterial enzyme activity. However, the microbiological findings were limited to culture-dependent analyses, and no mechanistic or comprehensive microbiome evaluations were performed. Therefore, further studies using advanced microbiome approaches and human clinical trials are warranted to better characterize the safety and potential probiotic effects of L. helveticus DLBSA201 and DLBSA202. Funding This study was fully supported by the Dexa Medica and the funder had no role in study design, and in data collection, analysis and interpretation. CRediT authorship contribution statement Tjandrawinata Raymond Rubianto: Writing – review & editing, Supervision. Medicia Kartawijaya: Writing – review & editing, Writing – original draft, Methodology, Formal analysis, Conceptualization. Hery Kristiana: Writing – review & editing, Writing – original draft, Methodology, Formal analysis, Conceptualization. Apriliana Wahyu Hartanti: Writing – review & editing, Writing – original draft, Methodology, Conceptualization. Lita Tuentifiany: Writing – review & editing, Writing – original draft, Methodology, Formal analysis, Conceptualization. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.